[A17-02] Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V
Last updated 18.04.2017
Project no.:
A17-02
Commission:
Commission awarded on 16.01.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-22 | Reslizumab (asthma) - Addendum to Commission A17-02 | Commission completed |